Research Identifies Potential New Biomarkers of Atherosclerotic Coronary Artery Disease
“This landmark result clearly demonstrates the power of causal AI and Digital Twins to reveal the hidden circuitry of cardiovascular disease from large-scale multi-omic data”, said Colin Hill, CEO and co-founder of Aitia. “Seventy years of cardiovascular biology including LDL, PCSK9, and Lp(a) were reconstructed in a hypothesis-free fashion in a few months, which created the […]
Becoming Aitia: Why GNS Shifted from AI Provider to Drug Discoverer
January 2023, GNS announced a rebrand as Aitia to focus on AI-enabled drug drug discovery. CEO Colin Hill told BioCentury the company considered the shift five years ago, seeing appetite from investors and pharma partners. “Aitia’s decision to move into drug discovery after more than 20 years as a technology partner is a bet on […]
New Biomarkers for Atherosclerosis Found Using Digital Twins
Newly identified markers of atherosclerotic coronary artery disease (ASCAD) were pinpointed in a study using digital twins. The work was carried out by multi-omics specialist G3 Therapeutics and AI company Aitia, which has Gemini Digital Twin technology. These new findings suggest triglyceride-rich LDL particles could be a novel diagnostic marker for ASCAD and could also […]
The Milken Institute Future of Health Summit – “Is AI Just What the Doctor-or Patient-Ordered?” Panel Discussion
The Milken Institute Future of Health Summit (FHS) convened the best minds in the world to confront the most significant health challenges by matching human, financial, and scientific resources with the most innovative, inclusive, and impactful ideas. Watch now the Future of Health Summit and the panel titled “Is AI Just What the Doctor-or Patient-Ordered?” […]